Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;79(3):661-666.
doi: 10.1002/jpn3.12236. Epub 2024 May 2.

Utilization and perspectives of weight loss medications in pediatric metabolic dysfunction-associated steatotic liver disease

Mohit Kehar  1 , Samar H Ibrahim  2 , Charina M Ramirez  3 , Saista Asif Amin  4 , Tamir Diamond  5 , Saeed Mohammad  6
Affiliations

Utilization and perspectives of weight loss medications in pediatric metabolic dysfunction-associated steatotic liver disease

Mohit Kehar et al. J Pediatr Gastroenterol Nutr. 2024 Sep.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing globally in pediatric populations. Currently, MASLD management primarily relies on lifestyle interventions, which pose challenges in sustaining long-term weight loss. This study investigated the use of weight loss medications in MASLD care through an international survey of 166 pediatric gastroenterologists and hepatologists. The results indicated a notable interest in weight loss medications, with 38% of practitioners considering or using them, particularly glucagon-like peptide-1 receptor agonists. However, the survey also revealed a tendency among clinicians to refer patients to specialists, emphasizing the potential gap between acknowledgment and prescription practices. Challenges include the lack of guidelines and uncertainty regarding side effects. The study highlights a pressing need for education, with over 90% of the respondents expressing an interest. Our study highlights the current management of MASLD, the potential role of pharmacotherapy, and highlights avenues for improved care and education in this dynamic field.

Keywords: MASLD; education; liver; pediatric; survey; weight loss.

PubMed Disclaimer

References

REFERENCES

    1. Hartmann P, Zhang X, Loomba R, Schnabl B. Global and national prevalence of nonalcoholic fatty liver disease in adolescents: an analysis of the global burden of disease study 2019. Hepatology. 2023;78(4):1168‐1181.
    1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966‐1986.
    1. Lazarus JV, Mark HE, Allen AM, et al. A global research priority agenda to advance public health responses to fatty liver disease. J Hepatol. 2023;79(3):618‐634.
    1. Shirazi F, Wang J, Wong RJ. Nonalcoholic steatohepatitis becomes the leading indication for liver transplant registrants among US adults born between 1945 and 1965. J Clin Exp Hepatol. 2020;10(1):30‐36.
    1. Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319‐334.

MeSH terms

Substances

Grants and funding

LinkOut - more resources